Complotype affects the extent of down-regulation by Factor I of the C3b feedback cycle in vitro

Clinical and Experimental Immunology

Volumn 181, Issue 2, 2015, Pages 314-322

  Lay, E ^a   Nutland, S ^b   Smith, J E ^c   Hiles, I ^c   Smith, R A G ^d   Seilly, D J ^a   Buchberger, A ^e   Schwaeble, W ^e   Lachmann, P J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

C3b feedback cycle; Complotype; Factor I

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR H; FIBRINOGEN; MIROCOCEPT; COMPLEMENT C3D,G; PEPTIDE FRAGMENT; ZYMOSAN;

AGE RELATED MACULAR DEGENERATION; ARTICLE; BLOOD SAMPLING; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; GENE FREQUENCY; GENOTYPE; GLOMERULOPATHY; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATORY DISEASE; PRIORITY JOURNAL; ALLELE; DRUG EFFECTS; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOTE; HOMOZYGOTE; IMMUNOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; COMPLEMENT C3B; COMPLEMENT FACTOR H; COMPLEMENT PATHWAY, ALTERNATIVE; FEEDBACK, PHYSIOLOGICAL; FIBRINOGEN; GENE EXPRESSION REGULATION; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; PEPTIDE FRAGMENTS; POLYMORPHISM, SINGLE NUCLEOTIDE; ZYMOSAN;

EID: 84947941249     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12437     Document Type: Article

References (20)

1. Alper CA, Propp RP. Genetic polymorphism of the third component of human complement (C′3). J Clin Invest 1968; 47:2181-2191.
2. Arvilommi H. Capacity of complement c3 phenotypes to bind on to mononuclear cells in man. Nature 1974; 251:740-741.
3. Heurich M, Martinez-Barricarte R, Francis NJ etal. Common polymorphisms in C3, factor B, and factor H collaborate to determine systemic complement activity and disease risk. Proc Natl Acad Sci USA 2011; 108:8761-8766.
4. Reynolds R, Hartnett ME, Atkinson JP, Giclas PC, Rosner B, Seddon J. Plasma complement components and activation fragments; associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci 2009; 50:5818-5827.
5. Harris CL, Heurich M, Rodriguez de Cordoba S, Morgan BP. The complotype: dictating risk for inflammation and infection. Trends Immunol 2012; 33:513-521.
6. Pickering MC, D'Agati VD, Nester CM etal. C3 glomerulopathy: consensus report. Kidney Int 2013; 84:1079-1089.
7. Sorensen H, Dissing J. Association between the C3F gene and atherosclerotic vascular diseases. Hum Hered 1975; 25:279-283.
8. Finn JE, Li Z, Agrawal S, Jayne DRW, Oliveira DBG, Mathieson PW. Molecular analysis of C3 allotypes in patients with systemic vasculitis. Nephrol Dial Transplant 1994; 9:1564-1567.
9. Lachmann PJ. The amplification loop of the complement pathways. Adv Immunol 2009; 104:115-148.
10. Lachmann PJ, Halbwachs L. The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol 1975; 21:109-114.
11. Nydegger UE, Fearon DT, Austen KF. The modulation of the alternative pathway of complement in C2-deficient human serum by changes in concentration of the component and control proteins. J Immunol 1978; 120:1404-1408.
12. Goicoechea de Jorge E, Caesar JJE, Malik TH etal. Dimerization of complement factor H-related proteins modulates complement activation in-vivo. Proc Natl Acad Sci USA 2013; 110:4685-4690.
13. Smith RAG. Targeting anticomplement agents. Biochem Soc Trans 2002; 30:1037-1041.
14. Walport M, Ng Yin C, Lachmann PJ. Erythrocytes transfused into patients with SLE and haemolytic anaemia lose complement receptor type 1 from their cell surface. Clin Exp Immunol 1987; 69:501-507.
15. Lachmann PJ. Preparing serum for functional complement assays.J Immun Methods 2010; 352:195-197.
16. Lachmann PJ, Pangburn MK, Oldroyd RG. Breakdown of C3 after complement activation. Identification of a new fragment, C3g, using monoclonal antibodies. J Exp Med 1982; 156:205-216.
17. Lachmann PJ, Oldroyd RG, Milstein C, Wright B. Three rat monoclonal antibodies to human C3. Immunology 1980; 41:503-515.
18. Harrison RA. Purification, assay, and characterization of complement proteins from plasma. In: Herzenberg LA, Weir DM, Herzenberg LA, Blackwell C, eds. Weir's handbook of experimental immunology, 5th edn, Chapter 75. Cambridge, MA, USA: Blackwell Science, 1996:1-50.
19. Ross GD, Lambris JD, Cain JA, Newman SL. Generation of three different fragments of bound C3 with purified Factor I or serum. Requirements for Factor H versus CR1 cofactor activity. J Immunol 1982; 129:2051-2060.
20. Smith RAG, Koffman G, Chowdhury P etal. Membrane localising complement inhibitors-clinical progress. Mol Immunol 2007; 44:3915.